EC approves Ordspono to treat r/r FL or r/r DLBCL

EU approves Calquence + chemo as first and only BTK inhibitor for first-line MLC

The European Medicines Agency approved Calquence (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma who are not eligible for autologous stem cell transplant.

May 09, 2025

Vol.51 No.18

Drugs & Targets

EC approves Lynozyfic for treatment of r/r multiple myeloma

The European Commission granted conditional marketing approval of Lynozyfic (linvoseltamab) to treat adults with relapsed and refractory multiple myeloma.

May 02, 2025

Vol.51 No.17

Drugs & Targets

CHMP adopts positive opinion for Adcetris + ECADD for newly diagnosed stage IIb/III/IV Hodgkin lymphoma

The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the extension of the marketing authorization of Adcetris (brentuximab vedotin) and recommended its approval in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone, a chemotherapy regimen, in adult patients with newly diagnosed stage 2b with risk factors/3/4 Hodgkin lymphoma.

May 02, 2025

Vol.51 No.17

Clinical Roundup

MSK and City of Hope researchers develop test using machine learning to help predict immunotherapy response in lymphoma

Researchers with Memorial Sloan Kettering and City of Hope have created a tool that uses machine learning to assess a non-Hodgkin lymphoma patient’s likely response to chimeric antigen receptor T-cell therapy before starting the treatment, according to study results published on April 1 in Nature Medicine.

April 11, 2025

Vol.51 No.14

Clinical Roundup

NK cells complexed with bispecific antibody yield high response rates in lymphoma

A novel cell therapy approach using cord blood-derived natural killer cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from the University of Texas MD Anderson Cancer Center.

April 11, 2025

Vol.51 No.14

Drugs & Targets

CHMP recommends approval of Calquence plus chemoimmunotherapy for first-line mantle cell lymphoma

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the EU for the treatment of adult patients with previously untreated mantle cell lymphoma who are not eligible for autologous hematopoietic stem cell transplantation.

April 04, 2025

Vol.51 No.13

EC approves Ordspono to treat r/r FL or r/r DLBCL

YOU MAY BE INTERESTED IN

EU approves Calquence + chemo as first and only BTK inhibitor for first-line MLC

EC approves Lynozyfic for treatment of r/r multiple myeloma

CHMP adopts positive opinion for Adcetris + ECADD for newly diagnosed stage IIb/III/IV Hodgkin lymphoma

MSK and City of Hope researchers develop test using machine learning to help predict immunotherapy response in lymphoma

NK cells complexed with bispecific antibody yield high response rates in lymphoma

CHMP recommends approval of Calquence plus chemoimmunotherapy for first-line mantle cell lymphoma

Renew today!

Subscriber content

Never miss an issue!

Login